Observational studyESMO open2023
Chemotherapy after nivolumab for advanced gastric cancer (REVIVE): a prospective observational study.
Y Narita et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
8 papers cite it
this papertrialcites it